Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors

Nature Reviews Drug Discovery

Volumn 2, Issue 7, 2003, Pages 517-526

  Tobert, Jonathan A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFUNGAL AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CERIVASTATIN; CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; COMPACTIN; CYCLOSPORIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; MEVALONIC ACID; MEVINOLIN; NEFAZODONE; NICOTINIC ACID; PLACEBO; PRAVASTATIN; PROBUCOL; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; TRIPARANOL; UNINDEXED DRUG;

CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DRUG APPROVAL; DRUG STRUCTURE; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; MYOPATHY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SLEEP DISORDER; ANIMAL; DRUG DESIGN;

ANIMALS; DRUG DESIGN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN;

EID: 0038004785     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1112     Document Type: Review

References (99)

1. Steinberg, D. & Gotto, A. M. Jr. Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. JAMA 282, 2043-2050 (1999).
2. Kannel, W. B. Clinical misconceptions dispelled by epidemiological research. Circulation 92, 3350-3360 (1995).
3. Keys, A. et al. The seven countries study: 2,289 deaths in 15 years. Prev. Med. 13, 141-154 (1984).
4. Peto, R., Yusuf, S. & Collins, R. Cholesterol-lowering trials in their epidemiological context. Circulation 72, 451 (1985).
5. NIH Consensus Development Conference. Lowering blood cholesterol to prevent heart disease. NIH Consensus Development Conference Statement. Nutr. Rev. 43, 283-291 (1985).
6. Kirby, T. J. Cataracts produced by triparanol. (MER-29). Trans. Am. Ophthalmol. Soc. 65, 494-543 (1967).
7. Endo, A., Kuroda, M. & Tsujita, Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. Antibiot. (Tokyo) 29, 1346-1348 (1976).
8. Endo, A., Tsujita, Y., Kuroda, M. & Tanzawa, K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur. J. Biochem. 77, 31-36 (1977).
9. Watanabe, Y. et al. Hypolipidemic effects of CS-500 (ML-236B) in WHHL-rabbit, a heritable animal model for hyperlipidemia. Atherosclerosis 38, 27-31 (1981).
10. Kuroda, M., Tsujita, Y., Tanzawa, K. & Endo, A. Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Lipids 14, 585-589 (1979).
11. Tsujita, Y., Kuroda, M., Tanzawa, K., Kitano, N. & Endo, A. Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Atherosclerosis 32, 307-313 (1979).
12. Fears, R., Richards, D. H. & Ferres, H. The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. Atherosclerosis 35, 439-449 (1980).
13. Singer, I. I., Scott, S., Kazazis, D. M. & Huff, J. W. Lovastatin, an inhibitor of cholesterol synthesis, induces hydroxymethylglutaryl-coenzyme A reductase directly on membranes of expanded smooth endoplasmic reticulum in rat hepatocytes. Proc. Natl Acad. Sci. 85, 5264-5268 (1988).
14. Bergstrom, J. D. et al. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin. Biochim. Biophys. Acta 1389, 213-221 (1998).
15. Alberts, A. W. et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl Acad. Sci. 77, 3957-3961 (1980).
16. Mabuchi, H. et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N. Engl. J. Med. 305, 478-482 (1981).
17. Mabuchi, H. et al. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. N. Engl. J. Med. 308, 609-613 (1983).
18. Tobert, J. A., Hitzenberger, G., Kukovetz, W. R., Holmes, I. B. & Jones, K. H. Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. Atherosclerosis 41, 61-65 (1982).
19. Tobert, J. A. et al. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, in healthy volunteers. J. Clin. Invest. 69, 913-919 (1982).
20. Bilheimer, D. W., Grundy, S. M., Brown, M. S. & Goldstein, J. L. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl Acad. Sci. 80, 4124-4128 (1983).
21. Illingworth, D. R. & Sexton, G. J. Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J. Clin. Invest. 74, 1972-1978 (1984).
22. Thompson, G. R., Ford, J., Jenkinson, M. & Trayner, I. Efficacy of mevinolin as adjuvant therapy for refractory familial hypercholesterolaemia. Q. J. Med. 60, 803-811 (1986).
23. Havel, R. J. et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann. Intern. Med. 107, 609-615 (1987).
24. Lovastatin Study Group II. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. JAMA 256, 2829-2834 (1986).
25. Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA 260, 359-366 (1988).
26. Lovastatin Study Group IV. A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. Am. J. Cardiol. 66, 22b-30b (1990).
27. Tang, J. L. et al. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 316, 1213-1220 (1998).
28. Bradford, R. H. et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch. Intern. Med. 151, 43-49 (1991).
29. Gerson, R. J. et al. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am. J. Med. 87, 28s-38s (1989).
30. Smith, P. F. et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J. Pharmacol. Exp. Ther. 257, 1225-1235 (1991).
31. Downs, J. R. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615-1622 (1998).
32. Coronary Drug Project. Clofibrate and niacin in coronary heart disease. JAMA 231, 360-381 (1975).
33. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251, 351-364 (1984).
34. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
35. Pedersen, T. R. et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch. Intern. Med. 156, 2085-2092 (1996).
36. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
37. Shepherd, J. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333, 1301-1307 (1995).
38. Sacks, F. M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001-1009 (1996).
39. The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 339, 1349-1357 (1998).
40. Serruys, P. W. J. C. et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA 287, 3215-3222 (2002).
41. Sever, P. S. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149-1158 (2003).
42. Chylack, L. T. Jr, Mantell, G., Wolfe, J. K., Friend, J. & Rosner, B. Lovastatin and the human lens; results of a two year study. The MSDRL Study Group. Optom. Vis. Sci. 70, 937-943 (1993).
43. Schmidt, J., Schmitt, C. & Hockwin, O. No lens changes caused by simvastatin results from a prospective drug safety study. Lens Eye Toxic. Res. 7, 643-650 (1990).
44. Harris, M. L. et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. Br. J. Ophthalmol. 79, 996-1002 (1995).
45. Schmidt, J., Schmitt, C., Hockwin, O., Paulus, U. & von Bergmann, K. Ocular drug safety and HMG-CoA-reductase inhibitors. Ophthalmic Res. 26, 352-360 (1994).
46. Laties, A. M. et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin. Am. J. Cardiol. 67, 447-453 (1991).
47. Tolman, K. The liver and lovastatin. Am. J. Cardiol. 89, 1374-1380 (2002).
48. LaRosa, J., He, J. & Vupputuri, S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282, 2340-2346 (1999).
49. Pedersen, T. R. et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am. J. Cardiol. 86, 257-262 (2000).
50. Eckernas, S. A. et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br. J. Clin. Pharmacol. 35, 284-289 (1993).
51. Kostis, J. B., Rosen, R. C. & Wilson, A. C. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J. Clin. Pharmacol. 34, 989-996 (1994).
52. Partinen, M. et al. Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia. Am. J. Cardiol. 73, 876-880 (1994).
53. Harrison, R. W. & Ashton, C. H. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br. J Clin. Pharmacol. 37, 231-236 (1994).
54. Gengo, F. et al. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin. Cardiol. 18, 209-214 (1995).
55. Wardle, J. et al. Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group. BMJ 313, 75-78 (1996).
56. Norman, D. J., Illingworth, D. R., Munson, J. & Hosenpud, J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N. Engl. J. Med. 318, 46-47 (1988).
57. Pierce, L. R., Wysowski, D. K. & Gross, T. P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 264, 71-75 (1990).
58. Gruer, P., Vega, J., Mercuri, M., Dobrinska, M. & Tobert, J. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am. J. Cardiol. 84, 811-815 (1999).
59. Ballantyne, C. M. et al. Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. 163, 553-564 (2003).
60. Brown, M. S. & Goldstein, J. L. A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34-47 (1986).
61. Pappu, A. S. & Illingworth, D. R. Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia. J. Lab. Clin. Med. 114, 554-562 (1989).
62. Naoumova, R. P. et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis 119, 203-213 (1996).
63. Brown, M. S. & Goldstein, J. L. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 21, 505-517 (1980).
64. Balasubramaniam, S., Goldstein, J. L. & Brown, M. S. Regulation of cholesterol synthesis in rat adrenal gland through coordinate control of 3-hydroxy-3-methylglutaryl coenzyme A synthase and reductase activities. Proc. Natl Acad. Sci. 74, 1421-1425 (1977).
65. Bergstrom, J. D., Wong, G. A., Edwards, P. A. & Edmond, J. The regulation of acetoacetyl-CoA synthetase activity by modulators of cholesterol synthesis in vivo and the utilization of acetoacetate for cholesterogenesis. J. Biol. Chem. 259, 14548-14553 (1984).
66. Kovanen, P. T., Bilheimer, D. W., Goldstein, J. L., Jaramillo, J. J. & Brown, M. S. Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc. Natl Acad. Sci. 78, 1194-1198 (1981).
67. Ma, P. T. et al. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc. Natl Acad. Sci. 83, 8370-8374 (1986).
68. Reihnér, E. et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N. Engl. J. Med. 323, 224-228 (1990).
69. Arad, Y., Ramakrishnan, R. & Ginsberg, H. N. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 41, 487-498 (1992).
70. Marais, A. D. et al. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J. Lipid Res. 38, 2071-2078 (1997).
71. Raal, F. J. et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis 135, 249-256 (1997).
72. Steinberg, D. The cholesterol controversy is over. Why did it take so long? Circulation 80, 1070-1078 (1989).
73. Muldoon, M. F., Manuck, S. B. & Matthews, K. A. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 301, 309-314 (1990).
74. Davey Smith, G. & Pekkanen, J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 304, 431-434 (1992).
75. Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 269, 3015-3023 (1993).
76. Pyörälä, K. et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur. Heart J. 15, 1300-1331 (1994).
77. Blankenhorn, D. H. et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann. Intern. Med. 119, 969-976 (1993).
78. MAAS investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 344, 633-638 (1994).
79. Waters, D. et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89, 959-968 (1994).
80. Jukema, J. W. et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91, 2528-2540 (1995).
81. Pitt, B. et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J. Am. Coll. Cardiol. 26, 1133-1139 (1995).
82. Furberg, C. D. et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group Circulation 90, 1679-1687 (1994).
83. Salonen, R. et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 92, 1758-1764 (1995).
84. Oliver, M. F. Serum cholesterol - the knave of hearts and the joker. Lancet 2, 1090-1095 (1981).
85. Oliver, M. F. Is cholesterol reduction always safe? Eur. J. Clin. Invest. 22, 441-442 (1992).
86. Oliver, M., Poole-Wilson, P., Shepherd, J. & Tikkanen, M. Lower patients' cholesterol now. BMJ 310, 1280-1281 (1995).
87. Collins, R. & MacMahon, S. Reliable assessment of the effects of treatment on mortality and major morbidity. I: clinical trials. Lancet 357, 373-380 (2001).
88. LaRosa, J. C. Pleiotropic effects of statins and their clinical significance. Am. J. Cardiol. 88, 291-293 (2001).
89. Vita, J. A. et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 102, 846-851 (2000).
90. Vollmer, T. et al. An open-label, single arm study of simvastatin as a therapy for multiple sclerosis (MS). 55th Annual Meeting of the American Association of Neurology Abstract S11. 004 (2003).
91. Raine, J. M. Withdrawal of cerivastatin (Libobay) by Bayer PLC. (Department of Health, Medicines Control Agency, London, 2001).
92. Editorial. How a statin might destroy a drug company. Lancet 361, 793 (2003).
93. Magarian, G. J., Lucas, L. M. & Colley, C. Gemfibrozil-induced myopathy. Arch. Intern. Med. 151, 1873-1874 (1991).
94. Backman, J., Kyrklund, C., Neuvonen, M. & Neuvonen, P. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72, 685-691 (2002).
95. Stein, E. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. Am. J. Cardiol. 82, 40j-46j (1998).
96. Yusuf, S. Two decades of progress in preventing vascular disease. Lancet 360, 2-3 (2002).
97. 12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr. Metab. Cardiovasc. Dis. 10, 195-203 (2000).
98. Davidson, M. H. Statin trials in progress: unanswered questions. Curr. Atheroscler. Rep. 3, 9-13 (2001).
99. Bruckert, E. New lipid-modifying therapies. Expert Opin. Investig. Drugs 12, 325-335 (2003).